SCHEMBL13428

SCHEMBL13428

CC(C)n1ncc2cc(Br)ccc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 3/20 0.48
ABCB1 P08183 1/20 0.41
ABCG2 Q9UNQ0 1/20 0.41
ACLY P53396 1/20 0.41
HTR2A P28223 2/20 0.41
HTR2C P28335 2/20 0.41
EZH2 Q15910 1/20 0.39
BRD4 O60885 1/20 0.37
CREBBP Q92793 1/20 0.37
CACNA1H O95180 1/20 0.36
MCL1 Q07820 1/20 0.36
NR3C1 P04150 1/20 0.35
PDE4B Q07343 1/20 0.35
SLC5A2 P31639 1/20 0.35
SLC6A2 P23975 1/20 0.35
KMO O15229 1/20 0.35
NOS1 P29475 1/20 0.34
METAP2 P50579 1/20 0.34
CSNK2A1 P68400 1/20 0.34
IRAK4 Q9NWZ3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30551304 1.00 HDAC8 (0.48) HDAC8ABCB1ABCG2ACLYHTR2A
SCHEMBL2144821 0.86 KMO (0.44) HDAC8ABCB1ABCG2ACLYHTR2A
SCHEMBL30381954 0.86 KMO (0.44) HDAC8ABCB1ABCG2ACLYHTR2A
SCHEMBL14910172 0.83 HDAC8 (0.44) HDAC8ABCB1ABCG2ACLYHTR2A
SCHEMBL30002750 0.83 HDAC8 (0.44) HDAC8ABCB1ABCG2ACLYHTR2A
SCHEMBL31444672 0.82 HDAC8 (0.43) HDAC8ABCB1ABCG2ACLYHTR2A
SCHEMBL23886616 0.82 HDAC8 (0.48) HDAC8HTR2AHTR2CMCL1NR3C1
SCHEMBL14236203 0.81 HDAC8 (0.47) HDAC8ABCB1ABCG2ACLYHTR2A
SCHEMBL14250555 0.80 HDAC8 (0.42) HDAC8HTR2AHTR2CBRD4CREBBP
SCHEMBL14015636 0.79 NR3C1 (0.42) HDAC8ABCB1ABCG2ACLYHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
US-20250163048-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-22 US disclosed
EP-4469455-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
EP-3912977-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES BioMarin Pharmaceutical Inc. (US) 2021-11-24 EP disclosed
EP-3046920-B1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARM INC (US) 2021-08-04 EP disclosed
EP-2714032-B1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORP (KR) 2019-01-16 EP disclosed
US-20140088079-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2014-03-27 US disclosed
US-20140088079-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2014-03-27 US disclosed
US-20140088079-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2014-03-27 US disclosed
US-8563543-B2 Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use MERCK SHARP & DOHME CORP. (US) 2013-10-22 US disclosed
US-8563543-B2 Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use MERCK SHARP & DOHME CORP. (US) 2013-10-22 US disclosed
WO-2012165914-A2 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2012-12-06 WO disclosed
WO-2012165914-A2 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2012-12-06 WO disclosed
US-20120189642-A1 IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE SCHERING CORPORATION (US) 2012-07-26 US disclosed
US-20120189642-A1 IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE SCHERING CORPORATION (US) 2012-07-26 US disclosed
WO-2011044187-A1 IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE SCHERING CORPORATION (US) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140088079-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS SLC5A2, SLC5A1, SLC2A8 HDAC8 911/4885ABCB1 444/4885ABCG2 154/4885
US-20250163048-A1 COMPOUNDS AND METHODS OF USE RB1, CYP1B1, REN HDAC8 2409/4885ABCB1 32/4885ABCG2 25/4885
US-20120189642-A1 IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE BACE1, APP, BACE2 HDAC8 4746/4885ABCB1 264/4885ABCG2 489/4885
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT HDAC8 596/4885ABCB1 2979/4885ABCG2 2974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.